Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

4SC Announces Positive Interim Results from Clinical Phase I/II SHORE Study

Published: Thursday, December 13, 2012
Last Updated: Wednesday, December 12, 2012
Bookmark and Share
Phase II part of study planned to start soon in 2013.

4SC AG has published positive interim results on safety, tolerability and pharmacokinetics from its clinical Phase I/II SHORE study with the anti-cancer compound resminostat in combination treatment with FOLFIRI chemotherapy in patients with advanced colorectal cancer (CRC).

The results successfully prove the safety and tolerability of the combined administration of resminostat and FOLFIRI.

This marks the achievement of the goal for the first part of the study (Phase I) and lays the foundations for commencing the study's Phase II part, which will assess the clinical efficacy of the resminostat-FOLFIRI-combination in advanced CRC patients.

Furthermore, the Phase I part of the study has already provided some initial encouraging data concerning the possible clinical benefit of this new therapeutic approach in this difficult-to-treat patient population.

These data showed that for some patients it was possible to administer the combination therapy over a comparatively long period of time - to a maximum of 33 weeks - while observing a stabilization of the tumour disease.

In the randomized, multi-centre, two-arm Phase II part of the SHORE study, planned to start soon in 2013, the combination therapy of resminostat with the FOLFIRI treatment regime will be assessed against sole treatment with FOLFIRI as a second-line treatment option for patients with advanced, KRAS-mutant colorectal cancer (CRC).

For this patient group, which constitutes around 40% of all patients with advanced CRC, there is a high medical need for new, additional therapy options.

In general, first-line therapy for advanced CRC patients consists of chemotherapy (FOLFOX or FOLFIRI) in combination with the drug Avastin®.

If, after a while, this therapy is no longer effective or tolerated - due to the development of resistance or the occurrence of side effects, for example - patients are switched over to second-line therapy.

In second-line, patients without a KRAS mutation have access to treatments aiming at the inhibition of epidermal growth factor receptor (EGFR) such as Erbitux® as a supplement to a further chemotherapy (FOLFIRI or FOLFOX).

However, CRC patients with a KRAS mutation in the EGFR pathway of their tumours, generally do not benefit from anti-EGFR therapy and, therefore, receive a chemotherapy such as FOLFIRI alone as second-line therapy.

Thus, for this KRAS-mutant CRC patient group there is a high medical need for new, supplementary therapy options which may be safely combined as second-line treatment with chemotherapy such as FOLFIRI to increase the latter's effectiveness - such as potentially resminostat.

Results from the Phase I part of the SHORE study
In the Phase I part of the SHORE study, a dose escalation for a total of 15 CRC patients to date was carried out to assess the safety and tolerability of a range of doses for resminostat up to 600 mg daily in combination with FOLFIRI, a multi-component chemotherapy regime that includes e.g. 5-fluorouracil (5-FU) and irinotecan, so as to determine the best possible dose for resminostat in combination with FOLFIRI. Pharmacokinetic parameters for resminostat and for the FOLFIRI components were also evaluated.

Resminostat proved to be generally safe and well-tolerated in all doses tested up to a daily single dosage of 600 mg in combination with the recommended standard dose from the FOLFIRI regime.

Accordingly, as regards combination therapy with FOLFIRI, the data confirmed the daily dosage of 600 mg already determined in earlier monotherapy and combination therapy studies with resminostat.

Observed side effects were generally mild to moderate and occurred, as expected, primarily as gastrointestinal and haematological effects.

FOLFIRI's known side-effect profile did not change as a result of the additional administration of resminostat. Furthermore, the study confirmed the compound's favourable pharmacokinetic profile which is, inter alia, reflected in the dose proportionality of resminostat blood levels - as already observed in other studies with resminostat.

No pharmacological interactions were observed between resminostat and the FOLFIRI components. The dosage of 600 mg for resminostat in combination with FOLFIRI is already being considered as a potential therapeutic dose for the Phase II part of the SHORE study.

In some patients in the Phase I part, it was possible to administer the combination therapy for several months (to a maximum of 33 weeks) while observing stabilization of the tumour disease. This substantiates the overall good tolerability and may also be considered as an initial indicator for the clinical benefit of this new therapeutic approach.

To allow for further expansion of the range of treatment options within this combination approach, a final, further dosage variant constituting the twice-daily administration of resminostat is currently under evaluation. This involves the clinical examination of a total daily dose of 800 mg of resminostat, taken as two doses of 400 mg in the morning and evening.

The medical-scientific rationale of the combination therapy of the epigenetically-active HDAC inhibitor resminostat - which can exert a substantial influence on key gene expressions - with traditional chemotherapy such as FOLFIRI, has been established on the basis of preclinical trials.

In these studies, resminostat combined with irinotecan, a component of the FOLFIRI regime, inhibited tumour growth more effectively than either substance when used as a monotherapy. It was also shown that resminostat - due to its gene regulatory properties - decreases the expression of the enzyme thymidylate synthase.

This enzyme triggers resistance mechanisms that target the compound 5-FU, which is an integral part of FOLFIRI. Accordingly, resminostat may work to sensitise tumour cells for treatment regimes containing 5-FU, such as FOLFIRI, as resminostat can be used to combat resistances that tumours have developed against 5-FU.

Dr Ulrich Dauer, Chief Executive Officer of 4SC, commented: 'We are pleased that the good safety and tolerability profile shown by resminostat in multiple Phase I and II studies has up to now also been confirmed in combination therapy with the FOLFIRI chemotherapy, and that we have already been able to treat some patients with advanced CRC over a period of several months with this new approach. We are particularly encouraged by the disease stabilization observed in individual patients. From our perspective, this constitutes a promising new therapeutic option for potential use in combination with FOLFIRI whose clinical efficacy we will now continue to evaluate next year in the randomized Phase II part of the SHORE study. K-RAS mutant patients, who account for 40% of all CRC patients, might particularly benefit from this additional therapeutic option since they have no access to EGFR-based therapies such as Erbitux® as a supplementary treatment to chemotherapeutics such as FOLFIRI in second-line CRC therapy.'


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

4SC Strengthens Patent Protection for its Epigenetic Cancer Drug Candidate 4SC-202
A selective inhibitor of LSD1 and HDACs 1, 2, and 3 - in China.
Tuesday, August 18, 2015
4SC Strengthens Patent Protection for Lead Cancer Compound Resminostat
US patent for medical use in cancer and Canadian composition of matter patent granted.
Wednesday, July 01, 2015
4SC's Partner Yakult Honsha Starts Clinical Phase I Study in Pancreatic Tract Cancer Patients
Safety, tolerability and efficacy of resminostat in combination with S-1 chemotherapy will be investigated in various dosing schemes in order to determine dose regimen for potential subsequent Phase II trials in advanced pancreatic and/or biliary tract cancer.
Friday, June 26, 2015
4SC Signs Licensing and Development Agreement with Menarini
Licensing partnership for 4SC's cancer compound resminostat for the Asia-Pacific region excluding Japan.
Thursday, April 16, 2015
Prof. Dr. Helga Rübsamen-Schaeff and Joerg von Petrikowsky Join 4SC AG
Prof. Dr. Rübsamen-Schaeff and Mr. von Petrikowsky will replace the Supervisory Board members Dr. Thomas Werner and Klaus Kühn.
Saturday, January 17, 2015
4SC Reports Positive Topline Data from Clinical Phase I Trial with 4SC-205
4SC-205 is the only oral inhibitor of the Eg5 kinesin protein in clinical development worldwide. Eg5 plays a crucial role in cell division and tumour growth.
Friday, December 12, 2014
4SC Further Strengthens Patent Protection for its Lead Compound Resminostat
US Patent granted for the manufacturing process of resminostat.
Tuesday, October 21, 2014
4SC's Partner Yakult Honsha Completes Phase I Part of Clinical Study with Resminostat in NSCLC Patients
Phase I confirms safety and tolerability of resminostat/docetaxel combination in the planned dose regimen in Asian NSCLC patients.
Saturday, October 11, 2014
CRELUX and 4SC Discovery Awarded Research Grant
Project for identifying new bromodomain inhibitors initiated under the Munich m4 biotech cluster programme.
Thursday, July 24, 2014
4SC Hires Experienced Pharmaceutical Manager and Oncology Expert
Dr Erich Enghofer joins 4SC in the newly created position of Executive Vice President.
Friday, July 04, 2014
4SC Announces Positive Top Line Data from Clinical Phase I TOPAS Study
Company will present data from Phase I trial with epigenetic cancer drug 4SC-202 in patients with haematological tumours at ASCO.
Friday, May 30, 2014
4SC Presents Results from Analysis of Biomarkers in Phase II SHELTER Trial in HCC
Oral presentation of detailed results at ILCA conference, 15 Sept. 2013, Washington D.C.
Friday, September 13, 2013
4SC's Partner Yakult Honsha Starts Clinical Phase I/II Study with Resminostat in NSCLC
The Phase I/II study will investigate safety and efficacy of resminostat/docetaxel combination vs. docetaxel alone as a novel treatment option for patients with advanced, metastatic, or recurrent NSCLC.
Thursday, July 25, 2013
4SC Expands Patent Protection for Epigenetic Anti-Cancer Compound
4SC AG announced that the company has significantly expanded international patent protection for 4SC-202 in the USA, China and Hong Kong.
Monday, July 15, 2013
4SC Gives Update on the Clinical Development of its Lead Cancer Compound Resminostat
Data from completed Phase I part of SHORE study confirms the safety of the resminostat FOLFIRI combination and showing encouraging signs of clinical benefit
Thursday, May 30, 2013
Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Searching Big Data Faster
Theoretical analysis could expand applications of accelerated searching in biology, other fields.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
How DNA ‘Proofreader’ Proteins Pick and Edit Their Reading Material
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have discovered how two important proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!